Humacyte, Inc. clinical trials
The registry lists 15 studies whose lead sponsor is Humacyte, Inc.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 15, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 15studies on the registry
- 3open to participants now
- 2phase 3 studies under way
- 1reach primary completion within a year
Get an email when these change. Save the Humacyte, Inc. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs Humacyte, Inc.’s studies test, most open studies first — 2 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- human acellular vessel extra-cellular matrix3 in phase 32 open · 4
- Hepatitis A virus2 in phase 30 open · 4
Coming up
1 of Humacyte, Inc.’s studies under way reach primary completion within a year, all of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- 1JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 15 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Humacyte, Inc..
- Humacyte, Inc.15 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 15 of 15.
- Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairNot yet recruitingNCT07762794Phase 4
- An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Not yet recruitingNCT07762313Phase 3
- Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)Not yet recruitingNCT07730528Phase 2
- Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis AccessTemporarily not availableNCT07141641
- Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisCompletedNCT02644941Phase 3
- Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaCompletedNCT03005418Phase 2/3
- To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisActive, not recruitingNCT05908084Phase 3
- Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisCompletedNCT03183245Phase 3
- Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System InjuriesApproved for marketingNCT03631056
- Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PADCompletedNCT02887859Phase 2
- An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular TraumaCompletedNCT05873959
- Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRDCompletedNCT01744418Not applicable
- Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PADCompletedNCT01872208Not applicable
- Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for DialysisCompletedNCT04135417Phase 2
- Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal DiseaseCompletedNCT01840956Phase 1